Longevity Is The Most Promising Investment Trend of 2024
In this edition, we explore how AI is sculpting our world into something extraordinary. From reshaping the space economy and redefining the healthcare landscape to revolutionizing longevity technology, we delve into a world where AI is not just a tool, but a transformational force. We’re charting the course of investment trends, uncovering the myriad ways AI is enhancing our lives, and confronting the ethical and practical implications of AI’s predictive power.
These topics not only highlight the ingenuity of modern science but also reflect our growing understanding of aging as a complex, yet increasingly manageable aspect of human life. This year, we stand on the brink of transformative breakthroughs that promise to reshape our approach to health and longevity, offering a glimpse into a future where aging is not just slowed, but enriched with quality and vitality.
Longevity Cities and The Investor Network
In today’s issue, we dive into the diverse and dynamic world of longevity investment, highlighting the remarkable progress and potential that lie ahead.
We explore the Longevity Investor Network’s remarkable growth and diversification, the transformative potential of Longevity Cities in reshaping our health and economic paradigms, and the exciting advancements in Alzheimer’s treatment spearheaded by Longeveron. Each of these narratives is not just a reflection of the progress made but a beacon pointing towards the profound possibilities that 2024 holds for longevity.
Saudi Arabia’s Global Longevity Revolution
Witness how Estée Lauder’s alliance with the Stanford Center on Longevity blurs the lines between aesthetic beauty and scientific research. Marvel at Saudi Arabia’s Hevolution Foundation, channeling an unprecedented investment into the realm of healthspan research. Be intrigued by the role of dietary elements in altering the course of aging, as revealed in recent mice studies.
Each narrative in this issue unfolds a layer of the complex tapestry of aging, portraying a future where longevity is synonymous with enhanced quality of life, rooted in scientific ingenuity and global cooperation.
Metformin, long known for its role in diabetes management, is now being reimagined as a key player in extending human lifespan. Rapamycin, a discovery from the soils of Easter Island, holds the intriguing potential to alter the course of aging at a cellular level. NAD, a cornerstone of cellular processes, presents a promising avenue in combatting age-related decline.
A Larger Market Than The iPhone – The Longevity Drug
As we dissect this report, we aim to bridge the gap between medical breakthroughs and financial foresight. Our analysis delves into the profound market potential of the aging drug, scrutinizes the intricacies of payer dynamics, and explores adoption trends, all through the lens of investment viability. This exploration is tailored for those intrigued by the convergence of healthcare innovation and strategic investment, offering insights into how longevity might reshape the economic landscape of the healthcare sector.
Longevity at Davos and A Missed Investment Opportunity
Our exploration begins with a deep dive into the critical yet often overlooked sector of women’s healthcare, revealing startling inequities and untapped potential. We then transition to a detailed recap of the pivotal discussions at the Longevity Investors Lunch in Davos, a forum where the brightest minds in longevity science converge to share insights and forge new paths. Our final destination is the innovative realm of Ventricle Health’s virtual cardiology clinic, a model of modern medical ingenuity. Each article not only highlights groundbreaking advancements but also brings to light the urgent need for equitable and inclusive healthcare practices.
We then pivot to the Global Healthspan Summit in Riyadh, where Hevolution Foundation’s staggering $40 million grant allocation signals a major leap in longevity. This initiative is a cornerstone in the quest to enhance global healthspan, underpinned by substantial financial commitment and international collaboration.
Lastly, we examine the PREDICTOM project’s significant funding for early Alzheimer’s detection. As dementia cases rise, this AI-driven endeavor stands as a beacon of hope and a testament to the power of collaborative innovation in tackling one of the most pressing health challenges of our time.
We then pivot to the Global Healthspan Summit in Riyadh, where Hevolution Foundation’s staggering $40 million grant allocation signals a major leap in aging research. This initiative is a cornerstone in the quest to enhance global healthspan, underpinned by substantial financial commitment and international collaboration.
Lastly, we examine the PREDICTOM project’s significant funding for early Alzheimer’s detection. As dementia cases rise, this AI-driven endeavor stands as a beacon of hope and a testament to the power of collaborative innovation in tackling one of the most pressing health challenges of our time.
$101 Million Longevity Prize Fund
This edition unveils a striking $101 million competition by the X Prize Foundation, set to revolutionize our approach to aging by focusing on holistic health improvements. We also spotlight the Forbes Technology Council’s compilation of 18 exceptional breakthroughs, ranging from Google and Harvard’s brain mapping to AI-driven therapeutic systems and CRISPR gene editing – each one a beacon of hope in our quest for enhanced healthcare and longevity. Additionally, we dive into the world of high-tech fitness with the CAROL Bike, a marvel in home exercise technology that combines the convenience of home workouts with the potency of cutting-edge science.
The Longevity and Crypto Island
In this special edition, we spotlight a biohacking startup in Honduras, blending cutting-edge gene therapy with the dynamic world of cryptocurrency, embodying a new frontier where medical progress meets financial experimentation. Next, we shift gears to a thought-provoking discussion from the Financial Times, challenging the conventional wisdom of GDP as the sole indicator of a nation’s progress, proposing life expectancy as a more comprehensive measure of national well-being. Finally, we dive into the World Bank’s insights on productive aging, unveiling how embracing an aging workforce can yield a ‘longevity dividend’, reshaping economies and societies at large.Through the lens of Sergey Jakimov of LongeVC, we investigate the strategic shift from lifespan to ‘healthspan,’ underpinning investments in life-extending biotechnologies. Amidst economic tumult, the longevity sector stands robust, defying trends with a Q3 2023 investment influx of $550m across 34 deals. We also spotlight the cultural zeitgeist, examining how the allure of longevity captures imaginations from “Succession’s” fictional elite to real-world moguls and everyday wellness routines.
(Exclusive) The Longevity Investor Report
Longevity is on track to be the most valuable sector in healthcare, with incredible market value estimates ranging from $600bn (Bank of America) to $2tn (McKinsey) by 2025. The Longevity Investor Report, coordinated by Multi-Fund General Partners, provides a complete sector breakdown focussed on the 10 key longevity investment areas.
The report provides free – for this limited edition – inside access to central notions, and companies, that professional investors are weighing up.
Abu Dhabi Investment Fund Bankrolls Longevity
This week, we delve into the captivating realm where big money meets groundbreaking science. Venture Capital giants are fervently backing initiatives in biotechnology, regenerative medicine, and AI, all aimed at prolonging life and enhancing health in our later years. From LongeVC to LifeX VC, major players are at the forefront, navigating the intricate web of financial risks and ethical considerations. We also spotlight Rejuveron Life Sciences AG, a Swiss biotech pioneer, supported by renowned investors and hedge fund tycoons, leading the charge in anti-aging research. And not least, we examine the bold move by Jeff Bezos, leveraging a portion of his immense wealth to fuel biotech startups aiming to revolutionize our approach to aging.
Through the lens of Sergey Jakimov of LongeVC, we investigate the strategic shift from lifespan to ‘healthspan,’ underpinning investments in life-extending biotechnologies. Amidst economic tumult, the longevity sector stands robust, defying trends with a Q3 2023 investment influx of $550m across 34 deals. We also spotlight the cultural zeitgeist, examining how the allure of longevity captures imaginations from “Succession’s” fictional elite to real-world moguls and everyday wellness routines.
Longevity Market To Reach $44.92 billion (!) by 2030
In this week’s edition, we delve into the investment vigor behind the longevity market, which has been said to be expected to reach $44.92 billion by 2030.
Through the lens of Sergey Jakimov of LongeVC, we investigate the strategic shift from lifespan to ‘healthspan,’ underpinning investments in life-extending biotechnologies. Amidst economic tumult, the longevity sector stands robust, defying trends with a Q3 2023 investment influx of $550m across 34 deals. We also spotlight the cultural zeitgeist, examining how the allure of longevity captures imaginations from “Succession’s” fictional elite to real-world moguls and everyday wellness routines.
